A novel “bimodel” use of icodextrin peritoneal dialysis solutions  by unknown
EDITORIAL
A novel “bimodal” use of icodextrin peritoneal dialysis solutions
With current technology, most peritoneal dialysis (PD) patients
can achieve the currently recommended minimal total solute
clearance goals [1] if one individualizes the PD prescription [2].
However, in some cases, the maximal clearances that can be
obtained practically are barely above these targets.
In this issue of the journal, Douma et al [3] describe the first
experience with the short-term use of peritoneal dialysis fluids
containing both the glucose polymer (GP) icodextrin and nitro-
prusside (NP). Comparing GP alone to the GP/NP combination,
they concluded that: (a) GP/NP solutions were well tolerated; (b)
for long dwells (. 3 hours), transcapillary ultrafiltration (TCUF)
was higher with the addition of NP; (c) net ultrafiltration (UF)
after an 8 hour dwell was 49% higher with GP/NP; and (d) there
was an increase in effective surface area and solute transport of all
solutes (including albumin). What is their reasoning and its
clinical significance?
In PD, solute removal is dependent on dialysate flow (that is,
drain volume), intrinsic peritoneal membrane (PM) permeability
to solutes and the effective PM surface area. Maintenance of
euvolemia has traditionally been an osmotically driven phenom-
enon via solutions made hypertonic to plasma using glucose as an
osmotic agent, a form of “crystalloid” osmosis. Unfortunately,
concurrent with the diffusion mediated transfer of solute from
blood to dialysate, there is absorption of glucose from the
peritoneum. Thus, during long dwells with glucose containing
solutions, the osmotic gradient is quickly dissipated, ultrafiltration
ceases and, unless the instilled fluid is drained, net fluid absorp-
tion via the peritoneal lymphatics predominates so that in some
cases drain volume and solute clearances are not optimized.
Hence, during long dwells, higher glucose concentrations and
their inherent metabolic complications are used to maintain UF.
With semipermeable membranes, osmotic flow is possible
between solutions if there is a difference in the size of the sum of
the products of the reflection coefficients and molar concentra-
tions of solutes on each side of the membrane via “colloid”
osmosis [4].
Icodextrin, a glucose polymer, isolated by hydrolyzed corn
starch as a mixture of oligopolysaccharides has been shown to be
an excellent “colloid” osmotic agent [5]. During PD, Icodextrin
was associated with slow but sustained net ultrafiltration through-
out the dwell. In a multicenter randomized study [6], it was shown
that at 8 hours, UF with the polymer was similar to that with
3.86% glucose (4.25% dextrose), suggesting that Icodextrin was a
safe and effective alternative osmotic agent which could poten-
tially replace hypertonic glucose for sustained UF during long
dwells.
Also significant is that GP solutions can be used as a vehicle for
“bimodal” solution preparation such as the one in this study. For
short dwells, net UF tends to be less than what can be achieved
with the crystalloid induced UF from glucose containing solutions.
Thus, combinations of “crystalloids” and “colloids” could be
adjusted to achieve a wide range of UF profiles for any dwell time
by adjusting the amount of small and large MW agents in the
solution. Many other potentially beneficial additives to PD solu-
tions (amino acids) are vasoactive. To maximize their effect,
sustained UF is needed. Initial studies have already been done
using GP combinations to explore these uses.
Douma et al [3]. have attempted to capitalize on the sustained
UF associated with GP. They found that by increasing the
effective peritoneal membrane surface area by adding NP (dis-
cussed later) to GP containing solutions, that one could augment
UF (from 344 mls to 540 mls) and increased solute clearances for
urea by 13% and for creatinine, 19% during an 8 hour dwell.
These changes could potentially increase weekly creatinine clear-
ance for an average 1.73 m2 patient by about 5 liters/week. Based
on the CANUSA study [7], this may decrease the predicted
mortality by 7%.
These 8-hour dwell UF/clearance data must be interpreted with
some caution. First of all, many CAPD patients have a longer
overnight dwell (9 or 10 hours). The daytime dwell for classic
CCPD is 13 to 15 hours. Although the sustained UF with GP is
likely to last for 14 to 16 hours, it is not known how long NP/GP
can sustain the increased UF observed. The authors note that the
D/P ratio of cGMP at 4 hours is higher than that after 8 hours.
This is likely due to absorption of the locally generated cGMP
from dialysate into the circulation, but could it also be due in part
to decreased cGMP conversion? The effect of nitric oxide (NO)
induced vasodilation is short. How sustained is the conversion to
NO? Further studies are needed.
The effective functional surface area is considerably less than
the anatomical surface area and is primarily determined by the
number of perfused capillaries which normally is only about 25%.
NP is readily metabolized by endothelium to NO. In smooth
muscles, NO then reacts with soluble guanylate cyclase resulting
in increased intracellular concentrations of cGMP with resultant
vascular relaxation, which increases peritoneal membrane surface
area, resultant diffusion and potentially UF. NO is quickly
oxidated to the stable inorganic nitrogen oxides, nitrite and
nitrate. With standard fluids/dwells this effect is mitigated because
of the associated increased glucose absorption [8]. Due to the
sustained UF with GP, one can achieve the potential positive
affect of adding NO. There are reasons to further explore this
combination.
It is uncertain if the human peritoneum normally produces NO.
Data from this study are consistent with the hypothesis that NP is
metabolized locally to NO which via cGMP causes vasodilatation
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and an increase in the effective PM surface area. What is not clear
is how long does the effect last (in hours), and is it eventually
sustained (months) or irreversible? If this increase in the effective
surface area is sustained over a 24 hour period, would not the
increased UF/clearance obtained by the GP/NP solution during
the overnight dwell be mitigated by 1.36% glucose solutions
(increased rapidity of glucose absorption) during the day? These
data were not reported.
One goal in the long-term patient is to prevent PM damage.
One of the first signs of PM damage with glucose containing
solutions is UF failure due to an increase in the effective surface
area (increased D/P Cr). With GP solutions is this change
beneficial, or is there a trade of for increased clearances/UF but
potential long-term damage? This short-term study cannot resolve
the possible concern about the increased albumin losses in the
dialysate [9] and emerging data that suggest that rapid transport-
ers have a higher relative risk of adverse outcome [10]. These
questions need further evaluation and were not addressed in this
study.
In summary, although for the average patient, GP may only
provide little clinically significant benefit over hypertonic glucose
solutions as far as solute clearance is concerned, they are likely to
allow one to obtain better blood pressure and volume control
without the need for hypertonic glucose and its associated meta-
bolic load. I command the authors for investigating further
“bimodal” solutions. The GP/NP solutions will likely be a further
benefit in promoting euvolemia and control of blood pressure in
PD patients, while slightly augmenting solute clearance especially
once RRF is lost. It is unknown what, if any, long-tern benefits GP
or GP/NP will have on the peritoneal membrane. Further long-
term studies are warranted.
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